NUVB · Nuvation Bio Inc.
$6.14
-2.23% last session
End-of-day data · close of 2026-09-11
Market cap
$2B
Enterprise value
$2B
Trailing P/E
—
Forward P/E
-418.7
Dividend yield
—
Beta
1.53
Avg volume
7M
Employees
0K
Daily Change %
-2.23%
5 Days Change
-4.26%
10 Days Change
-2.10%
30 Days Change
2.35%
60 Days Change
12.22%
Month to Day Change
-1.81%
Year to Day Change
-27.23%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — NUVB
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-08-21
Latest call per bank · past 12 months
JP Morgan
Overweight$13.00
+107.0% vs priceRBC Capital
Outperform$20.00
+218.5% vs priceUBS
Neutral$7.00
+11.5% vs priceJefferies
Buy$10.00
+59.2% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-21 | Cantor Fitzgerald | Initiates | Overweight | $0.00 |
| 2026-08-18 | JP Morgan | Initiates | Overweight | $0.00 → $13.00 |
| 2026-08-07 | RBC Capital | Maintains | Outperform | $19.00 → $20.00 |
| 2026-07-27 | HC Wainwright & Co. | Maintains | Buy | $17.00 → $21.00 |
| 2026-07-23 | Wedbush | Reiterates | Outperform | $11.00 |
| 2026-07-07 | RBC Capital | Maintains | Outperform | $20.00 → $19.00 |
| 2026-07-07 | Truist Securities | Maintains | Buy | $12.00 → $13.00 |
| 2026-05-05 | RBC Capital | Reiterates | Outperform | $20.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 41 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 4.2% below the 50-day MA ($6.41).
- Price vs 200-day MA: Trading 3.2% above the 200-day MA ($5.95).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.10) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($3.01) and high ($9.54).
NUVB Price Chart
Loading chart for NUVB…
Fundamentals
About Nuvation Bio Inc.
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$130B 14.9% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$82B 5.0% YTD
ARGX
argenx SE
$62B 19.2% YTD
MRNA
Moderna, Inc.
$55B 359.9% YTD
RVMD
Revolution Medicines, Inc.
$44B 160.7% YTD
ONC
BeOne Medicines Ltd.
$39B 15.5% YTD
RPRX
Royalty Pharma plc
$34B 59.0% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$33B -35.1% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.